Study S001855

A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT03060980
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: TERMINATED
Enrollment: 245
Start: 2017-03-03
Primary completion: 2018-01-26
Lead sponsor: Intarcia Therapeutics
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:ITCA 650 20/60 mcg/day; DRUG:Empagliflozin (oral); DRUG:Glimepiride (oral)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Reduction in glycosylated hemoglobin A1c [Randomization to 69 weeks]
Reduction in weight [Randomization to 69 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.